Status:
COMPLETED
Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients
Lead Sponsor:
Gary E. Stein, Pharm.D.
Conditions:
Febrile Neutropenia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Primary: To determine the serum pharmacokinetics (PK) of doripenem in febrile neutropenic patients. Secondary: Monte Carlo Simulations Tested Against Various Gram-negative Isolates and Reported as Pr...
Detailed Description
Background: Doripenem is a group 2 carbapenem with enhanced in vitro activity against Gram-negative bacteria including Pseudomonas aeruginosa. Currently, there is a paucity of pharmacokinetic/pharmaco...
Eligibility Criteria
Inclusion
- adult neutropenic (\< 500 cells) patients who are febrile
Exclusion
- Patients with Creatinine Clearance \< 30 ml/min or allergy to carbapenems will be excluded.
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01401010
Start Date
August 1 2010
End Date
February 1 2012
Last Update
October 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sparrow Hospital
Lansing, Michigan, United States, 48910